5-amino-1-(6-chloro-3-pyridazinyl)-1H-pyrazole-4-carboxylic acid ethyl ester | 69720-12-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-amino-1-(6-chloro-3-pyridazinyl)-1H-pyrazole-4-carboxylic acid ethyl ester
• 英文别名: ethyl 5-amino-1-(3-chloropyridazin-6-yl)-1H-pyrazole-4-carboxylate；5-amino-1-(6-chloro-pyridazin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester；5-amino-1-(6-chloro-pyridazin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester；3-chloro-6-(4-ethoxycarbonyl-5-amino-1-pyrazolyl)-pyridazine；ethyl 5-amino-1-(6-chloropyridazin-3-yl)-1H-pyrazole-4-carboxylate；ethyl 5-amino-1-(6-chloropyridazin-3-yl)pyrazole-4-carboxylate
• CAS: 69720-12-3
• 化学式: C₁₀H₁₀ClN₅O₂
• mdl: MFCD00219046
• 分子量: 267.675
• InChiKey: TXXNCHKKIABOJX-UHFFFAOYSA-N

物化性质

• 熔点：
  133-134 °C
• 沸点：
  490.7±45.0 °C(Predicted)
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  95.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-amino-1-(6-chloro-3-pyridazinyl)-1H-pyrazole-4-carboxylic acid ethyl ester 在 一水合肼 作用下， 以 1,4-二氧六环 为溶剂， 生成 5-amino-1-(6-hydrazino-pyridazin-3-yl)-1H-pyrazole-4-carboxylic acid hydrazide
  参考文献：
  名称：

  3-(1-Pyrazolyl)-pyridazine derivatives

  摘要：

  化合物I的3-(1-吡唑基)-吡嗪衍生物或其药学上可接受的酸加成盐，可降低高血压并抑制前列腺素的分解，式中R1为氢或C1-4烷基，R2为氢、氰、羧基、氨基甲酰基、羧甲氧基或C1-4烷氧羧基，R3为氢或氯或--NR4NHR5或NR6R7，其中R4和R5均为氢或C1-4烷基，R6和R7均为氢或C1-5烷基、C1-5羟基烷基、C3-7环烷基、苯基或苄基，或带有一个或两个氯原子或甲氧基取代的苄基或苯乙基，或为呋喃甲基、吡啶甲基、吡咯烷或哌嗪环，当R7为氢时，R6为--(CH2)n--NR4R5，其中n为1至3的整数。

  公开号：

  US04251658A1
• 作为产物：
  描述：

  3-氯-6-肼基哒嗪 、 2-氰基-3-乙氧基丙烯酸乙酯 以 乙醇 为溶剂， 反应 3.5h， 以81%的产率得到5-amino-1-(6-chloro-3-pyridazinyl)-1H-pyrazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  Sunder, Shyam; Peet, Norton P., Journal of Heterocyclic Chemistry, 1980, vol. 17, # 6, p. 1527 - 1529

  摘要：

  DOI：

文献信息

• Acylated indanyl amines and their use as pharmaceuticals
  申请人：——

  公开号：US20030055093A1

  公开（公告）日：2003-03-20

  The present invention relates to acylated indanyl amines according to the general formula (I) 1 wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B is CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式（I）中的酰化的茚基胺，其中R1-R4具有描述中给出的含义，A为CH2、CHOH或CH—（C1-C3-烷基），B为 或CH—（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物在上调内皮型一氧化氮合酶（eNOS）方面有用，因此可能用于制造用于治疗心血管疾病、稳定或不稳定心绞痛、冠心病、普林兹梅塔心绞痛、急性冠状综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、骨质疏松症、记忆力受限、学习能力受限，或用于降低绝经后妇女或口服避孕药后心血管风险。
• ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20070082897A1

  公开（公告）日：2007-04-12

  The present invention relates to acylated indanyl amines according to the general formula (I) wherein R 1 —R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B is CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式（I）的酰化吲哚基胺，其中R1-R4具有描述中给出的含义，A为CH2，CHOH或CH-（C1-C3-烷基），B为 或CH-（C1-C3-烷基），而R5为芳基或杂芳基基团，可能被描述中列出的取代基所取代。这些化合物有助于上调内皮型一氧化氮合酶（eNOS），因此可能用于制造用于治疗心血管疾病、稳定或不稳定型心绞痛、冠心病、普林兹梅塔尔心绞痛、急性冠状动脉综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞症、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后的内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾衰竭、肝硬化、骨质疏松症、受限制的记忆表现、受限制的学习能力或降低绝经后妇女或口服避孕药后的心血管风险。
• Synthesis, Antibacterial and Antioxidant Properties of Pyrazolylpyridazines
  作者：Abdul Qayuum Ather

  DOI：10.14233/ajchem.2013.14590

  日期：——

  A number of 6-chloro-3-(pyrazol-1'-yl) pyridazines were prepared from 3,6-dichloropyridazine via either reaction with hydrazine followed by reaction with appropriate reagents to develop the pyrazole or through a nucleophilic reaction with a pyrazole. Some electrophilic reactions gave the corresponding 4'-substituted pyrazolylpyridazines. All the compounds were tested for their in vitro antibacterial as well as their antioxidant properties.
• SZILAGYI G.; KASZTREINER E.; TARDOS L.; JASZLITS L.; KOSA E.; CSEH G.; TO+, EUR. J. MED. CHEM.-CHIM. THER., 1979, 14, NO 5, 439-445
  作者：SZILAGYI G.、 KASZTREINER E.、 TARDOS L.、 JASZLITS L.、 KOSA E.、 CSEH G.、 TO+

  DOI：——

  日期：——
• SUNDER S.; PEET N. P., J. HETEROCYCL. CHEM., 1980, 17, NO 7, 1527-1529
  作者：SUNDER S.、 PEET N. P.

  DOI：——

  日期：——